Albert Wang

Represented ACT Genomics, a world-leading cancer solution provider, in its migration and Series C financing.

Represented MediaTek (TWSE: 2454), a global fabless semiconductor company, in its asset sale and technology licensing agreement with Ili Technology Corp. for the sale of business assets and the licensing of technology related to discrete timing-controller technology.

Represented Gorilla Technology Group Inc. (NASDAQ: GRRR), an Edge AI, security intelligence, network intelligence, and IoT technology company, in a de-SPAC transaction pursuant to which blank check company Global SPAC Partners Co. merged with a subsidiary of Gorilla.

Represented Prenetics (NASDAQ PRE), a Hong Kong-based leading genomics-driven health sciences company, on the sale of ACT Genomics Holdings Company Limited to Delta Electronics Inc (2308.TW) for approximately US$72 million.

Represented Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, in connection with a privatization project of US$300 million value conducted through share swap transactions with Woods Investment, with sources of funds from its major shareholders and PAG, a global alternative investment firm. It successfully delisted from both Taipei Exchange and NASDAQ and the privatization project was completed on 8 October 2021.

Assisted Taiwan Liposome Company with its IPO in the United States, listing American Depository Shares representing common shares.